Published in Neth Heart J on November 01, 2001
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 4.15
Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation (1997) 4.09
Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet (1995) 3.67
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol (1998) 3.03
Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA (1999) 1.86
Percutaneous septal ablation for hypertrophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr (2000) 1.74
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation (1998) 1.54
Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg (1999) 1.01
Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol (1998) 0.99
Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv (1999) 0.87
Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation (1997) 4.09
Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart (2000) 1.56
Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation (1998) 1.54
Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol (2004) 1.53
[Therapy of hypertropic obstructive cardiomyopathy]. Dtsch Med Wochenschr (1996) 1.39
One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol (2007) 1.35
Traumatic sinus of Valsalva fistula and aortic valve rupture. Ann Thorac Surg (1993) 0.99
Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol (2005) 0.88
Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. J Am Soc Echocardiogr (2000) 0.88
Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv (1999) 0.87
[Catheter treatment of hypertrophic obstructive cardiomyopathy]. Dtsch Med Wochenschr (1996) 0.81
Glycoprotein IIb/IIIa antagonists during carotid artery stenting: results from the carotid artery stenting (CAS) registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). Clin Res Cardiol (2007) 0.80
[Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertrophic cardiomyopathy]. Z Kardiol (2003) 0.79
[Diagnosis and differential therapy of mitral stenosis]. Herz (1998) 0.79
Improvement of survival rate in patients with cardiogenic shock by using nonpulsatile and pulsatile ventricular assist device. Int J Artif Organs (1992) 0.79
Percutaneous transluminal septal myocardial ablation: a new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J (2000) 0.78
Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. Am J Cardiol (1990) 0.77
[Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy ]. Dtsch Med Wochenschr (2008) 0.77
[Congenital coronary artery aneurysm: a rare cause of acute myocardial infarct]. Z Kardiol (1996) 0.76
[Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results in 66 patients with reference to myocardial contrast echocardiography]. Z Kardiol (1998) 0.75
The management of hypertrophic cardiomyopathy. N Engl J Med (1997) 0.75
Serial septal branch assessment in hypertrophic obstructive cardiomyopathy: New echocardiographic contrast agent for alcohol septal ablation. Herz (2013) 0.75
Percutaneous alcohol ablation in HOCM. Catheter Cardiovasc Interv (1999) 0.75
Contrast echocardiography during alcohol septal ablation: friend or foe? Heart (2005) 0.75
Localized benign mesothelioma of the pleura: case report and review of the literature. Thorac Cardiovasc Surg (1986) 0.75
[Long-term follow-up after acute myocardial infarct cause by non-arteriosclerotic spontaneous coronary artery dissection]. Z Kardiol (1996) 0.75
[Percutaneous transluminal coronary angioplasty or surgical revascularization in coronary heart disease?]. Dtsch Med Wochenschr (1994) 0.75
[Esophageal ulcer caused by mexiletine]. Dtsch Med Wochenschr (1983) 0.75
[Transvenous closure of persistent ductus arteriosus with an Ivalon plug]. Dtsch Med Wochenschr (1996) 0.75
[Clinical picture and therapy of hypertrophic cardiomyopathy]. Med Klin (Munich) (1998) 0.75
[The percutaneous extraction of an embolized Pudenz-Heyer catheter fragment from the pulmonary artery]. Dtsch Med Wochenschr (1992) 0.75
[Emergent percutaneous mitral valve repair with Inoue balloon-catheter in severe mitral stenosis and cardiogenic shock]. Dtsch Med Wochenschr (1994) 0.75
[Emergency percutaneous valvulotomy with the Inoue balloon in high grade mitral valve stenosis in pregnancy]. Med Klin (Munich) (1998) 0.75
[Clinical significance of the cardiovascular risk factor fibrinogen in secondary prevention]. Versicherungsmedizin (1995) 0.75
Assessment of myocardial scarring by contrast enhanced magnetic resonance imaging in a patient 11 years after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Int J Cardiol (2009) 0.75